Rebecsinib

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameRebecsinib
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy
Mechanisms of ActionAdenosine Deaminase Acting On RNA 1-A inhibitors
TargetsAdenosine Deaminase Acting On RNA 1-A
Therapy Area/IndicationsPrimary MyelofibrosisLeukemia, Myeloid, AcuteNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of California, San Diego, Department Of Pediatrics
China Registration ClassN/A

Develop Information

Active CompaniesAspera Biomedicines Inc
Inactive CompaniesUniversity Of California, San Diego, Department Of Pediatrics
Active IndicationsPrimary MyelofibrosisLeukemia, Myeloid, Acute
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A